The 22q11.2 deletion syndrome (22q11.2DS) is a multisystem condition and the most prevalent microdeletion syndrome in humans. Approximately 25% of individuals with 22q11.2DS receive antipsychotic treatment. To assess whether patients with 22q11.2DS are vulnerable to adverse effects of antipsychotic medication, we carried out a literature review.
alence of approximately 1 in 3000 live births, it is the most prevalent microdeletion syndromes in humans (Devriendt, Fryns, Mortier, Van Thienen, & Keymolen, 1998; Scambler, 2000) . The 22q11.2 deletion mostly occurs de novo, and in the majority of cases the size of the deletion is around 3 Mb (McDonald-McGinn et al., 2015) . Independent of deletion size, the 22q11.2DS phenotype is highly variable.
Common features include neurodevelopmental disorders and major birth defects such as congenital heart defects and submucous cleft palate, in addition to later-onset conditions such as obesity and Parkinson's disease (Bassett et al., 2011; Fung et al., 2015; Voll et al., 2017) . Endocrine problems and neuropsychiatric disorders are common manifestations, with the lifetime prevalence of schizophrenia in 22q11.2DS estimated to be up to 41% in adults (Schneider et al., 2014) .
Although many patients with 22q11.2DS receive antipsychotic treatment for psychotic disorders or behavioral problems, little is known about the safety and tolerability of antipsychotics in people with 22q11.2DS. Current guidelines recommend following treatment
| Inclusion criteria
Publications were included when the following inclusion criteria were met: (a) the paper reported on a trial, cohort study or case report with specific mention of adverse events related to antipsychotic use;
(b) the study included one or more patients with a molecularly confirmed diagnosis of 22q11.2DS; (c) the study was published in a peerreviewed journal or conference book. Quality of the included studies was assessed independently by J.B. and L.G. using the Cochrane Risk of Bias tool for harm studies (Higgins & Altman, 2008) or the tool for evaluating the methodological quality of case reports and case series (Murad, Sultan, Haffar, & Bazerbachi, 2018) , dependent on the type of study (Table S2 and Table S3 , respectively).
| RESULTS
A flow diagram of the literature search is depicted in Figure 1 reported on adverse events associated with antipsychotic use in patients with 22q11.2DS. After reading the full text of these 77 articles, 40 publications fulfilled inclusion criteria of which 11 (reporting on 8 studies) described trials, cross-sectional or cohort studies (see Table 1 for descriptive information; Butcher, Fung, Cheung, et al., 2013; Butcher, Marras, Pondal, et al., 2014; Butcher, Fung, Fitzpatrick, Guna, Andrade, Lang, et al., 2015; Butcher, Fung, Fitzpatrick, Guna, Andrade, Lang, & Chow, 2015; Dori et al., 2017; Kawano et al., 2014; Verhoeven & Egger, 2015; Voll et al., 2017; . None of the included studies were randomized or blinded in design. Additionally, 30 case reports (Aksu & Demirkaya, 2016; Angelopoulos et al., 2017; Biswas, Hands, & White, 2008; Borders, Suzuki, & Safani, 2017; Briegel, 2007; Butcher et al., 2014; Demily, Poisson, Thibaut, & Franck, 2017; Engebretsen, Kihldal, & Bakken, 2015; Faedda, Wachtel, Higgins, & Shprintzen, 2015; Farrell et al., 2018; Gagliano & Masi, 2009; Gladston & Clarke, 2005; Gothelf et al., 1999; Jacobson & Turkel, 2013; Kontoangelos, Maillis, Maltezou, Tsiori, & Papageorgiou, 2015; Kook et al., 2010; Krahn, Maraganore, & Michels, 1998; Le Page, 2006; Molebatsi & Olashore, 2018; Muller & Fellgiebel, 2008; O'Hanlon, Ritchie, Smith, & Patel, 2003; Ohi et al., 2013; Perret et al., 2017; Praharaj & Sarkar, 2010; Ruhe, Qureshi, & Procaccini, 2018; Sachdev, 2002; Starling & Harris, 2008; Thomas, 2003; Yacoub & Aybar, 2007) were included, summarized in Table 2 . One publication described both a crosssectional study and a case report (Butcher et al., 2014) , and is therefore included in both Tables 1 and 2 . The most commonly reported symptoms that were potentially related to antipsychotic medication and that may have clinical implications were classified into the following categories: movement disorders, seizures, weight gain, cardiac side effects, and cytopenias. The main results for each of these categories are discussed separately. For a detailed overview see Table 2 .
| Movement disorders
Extrapyramidal symptoms were frequently reported in individuals with 22q11.2DS treated with antipsychotics. In 19 patients who together received 35 trials with risperidone, olanzapine, and quetiapine (Dori et al., 2017) , extrapyramidal symptoms were reported in nine of the 35 (25.7%) trials. No information was provided on whether extrapyramidal symptoms occurred more often during treatment with either risperidone, olanzapine or quetiapine. The severity or the type of motor symptoms was also not reported. Notably, although clozapine is generally considered to be practically free of motor side effects (Casey, 1989; Rummel-Kluge et al., 2010) , several case studies reported extrapyramidal symptoms in patients on monotherapy with clozapine Gagliano & Masi, 2009; Gladston & Clarke, 2005; Krahn et al., 1998; Ruhe et al., 2018) , see Table 2 . Noteworthy, there was one case report of a 27-year-old man with increasing parkinsonism (including bradykinesia, rigidity, and rest tremor) while on clozapine treatment (Krahn et al., 1998) . The progressive nature of his symptoms however suggested that these symptoms were not primarily drug induced. Myoclonus was reported in several case reports under clozapine Butcher et al., 2014; Gladston & Clarke, 2005; Gothelf et al., 1999) , and in one case under olanzapine treatment (Sachdev, 2002) . Dystonia was reported during treatment with amisulpride (Starling & Harris, 2008) , haloperidol (Kontoangelos et al., 2015) , risperidone (Perret et al., 2017) , asenapine (Borders et al., 2017) olanzapine Perret et al., 2017) , and quetiapine .
| Seizures
Seizures were reported after the start of quetiapine , aripiprazole , risperidone (Kook et al., 2010) , and clozapine (Aksu & Demirkaya, 2016; Briegel, 2007; Gladston & Clarke, 2005; Krahn et al., 1998; Yacoub & Aybar, 2007) (Butcher, Fung, Fitzpatrick, Guna, Andrade, Lang, & Chow, 2015) . Out of the 17 case reports of individuals treated with clozapine that fulfilled inclusion criteria for this review, five cases (29.4%) reported tonic-clonic seizures (Aksu & Demirkaya, 2016; Boot, Butcher, Vorstman, et al., 2015; Briegel, 2007; Krahn et al., 1998; Yacoub & Aybar, 2007) . In a retrospective chart review study in 202 adults with 22q11.2DS it was found that 21 of the 119 patients (17.6%) on psychotropic drugs experienced one or more seizures, and 16 patients (50% of the patients with seizures) experienced their first seizure while taking an antipsychotic . The antipsychotic most commonly associated with seizures was clozapine 
| Weight gain
Weight gain was mostly reported in patients that use risperidone (Borders et al., 2017) , quetiapine (Starling & Harris, 2008) , olanzapine (Faedda et al., 2015; Perret et al., 2017; Starling & Harris, 2008) , and clozapine (Gagliano & Masi, 2009 ). Weight gain was the second most frequent adverse effect reported in five (14.2%) out of the 35 trials with risperidone, quetiapine, and olanzapine (Dori et al., 2017) . In a study in 207 adults with 22q11.2DS, it was found that psychotropic medication use, including but not exclusively antipsychotics, increased the odds of developing obesity with~2.5 times relative to those without psychotropic medication (Voll et al., 2017) .
| Cardiac adverse effects
Two cases of clozapine-induced myocarditis, expected to occur iñ 3% of patients on clozapine in general (Ronaldson, Fitzgerald, & McNeil, 2015) , have been reported in patients with 22q11.2DS (Boot, Butcher, Vorstman, et al., 2015; Ruhe et al., 2018) . In addition, one case report described the development of QT prolongation after This case report describes a 2-year-old with recurrent pneumonia, a prior seizure, pulmonary hypertension, and right heart failure. The child underwent surgical repair of congenital cardiac defects. Psychiatrists were consulted to assist with managing the delirium while she was intubated and sedated.
sertraline was added to treatment with quetiapine and risperidone, which normalized after discontinuation of sertraline (Dori et al., 2017) .
| Cytopenias
In a retrospective study that looked at the response profile to clozapine, three (15%) of the 20 patients presented with severe neutropenia, while no neutropenia was seen in the patients with idiopathic psychosis (Butcher, Fung, Fitzpatrick, Guna, Andrade, Lang, & Chow, 2015) . Neutropenia associated with clozapine use was also reported in two case reports (Gagliano & Masi, 2009; Le Page, 2006) , in one case leading to agranulocytosis (Le Page, 2006) . It must be noted that the child (aged 7 years) described in the first case report (Gagliano & Masi, 2009 ) also used aripiprazole and tamoxifen; neutropenia has been reported as a side effect of both drugs in patients without 22q11.2DS (Felin, Naveed, & Chaudhary, 2018; Miké, Currie, & Gee, 1994) . Leukopenia was reported with the use of olanzapine monotherapy and clozapine monotherapy (Engebretsen et al., 2015) .
Thrombocytopenia has been reported in many patients that used clozapine (Farrell et al., 2018; Praharaj & Sarkar, 2010) , risperidone (Farrell et al., 2018 ), haloperidol (Le Page, 2006 , olanzapine (Farrell et al., 2018; O'Hanlon et al., 2003; Praharaj & Sarkar, 2010) , and perphenazine (Farrell et al., 2018) .
| Critical appraisal
The quality of the trials, cross-sectional and cohort studies (see Table S2 ) was highly variable. Most studies were retrospective in nature, and patients and assessors were not blinded to either treatment or outcome. Study objectives differed among the included studies; assessing the safety and tolerability of antipsychotics was not the main objective for all studies. Furthermore, most studies did not apply corrections for possible confounders, and patient selection was mostly unclear. It is noted that some studies reported on partly overlapping cohorts, therefore we combined those references in our results section (see Table 1 ).
Critical appraisal of the case reports is described in Table S3 . It is noted that only two out of 30 case reports performed a challengerechallenge approach. Also, dose-response relations were scarcely reported (n = 4). Most case reports did not assess the possibility of alternative causes for the reported symptoms. These aspects are essential in determining the likelihood of a causal relation between symptoms and medication use. Therefore, the evidence derived from the case reports remains inconclusive.
| DISCUSSION
This study is the first to provide a systematic overview of the literature specifically on reported adverse effects of antipsychotic medication in patients with a 22q11.2DS. Symptoms that were reported as (possible) adverse effects were movement disorders, seizures, weight change, cardiac side effects and cytopenias. These symptoms are also known adverse effects of antipsychotics in the nondeleted (general) population. While there is an abundance of case reports, research to this date is merely observational in nature and randomized and/or controlled trials are lacking.
The only study that directly compared the tolerability to antipsychotics in adults with 22q11.2DS to patients without a 22q11.2 deletion (Butcher, Fung, Fitzpatrick, Guna, Andrade, Lang, & Chow, 2015) reported that half of the 22q11.2DS group (n = 10, 50%) experienced at least one serious adverse event under treatment with clozapine compared with none of the idiopathic group (gender-adjusted OR = 16.5, 95% CI 1. 8-149.8) . Reported adverse events included myocarditis (n = 1, 5%), severe neutropenia (n = 3, 15%) and seizures (n = 8, 40%). However, in this retrospective study, no challengerechallenge or dose-response effects were reported.
Our findings are consistent with a recent review that examined effectiveness and side effects of psychiatric medication in individuals with 22q11.2 deletion syndrome with comorbid psychiatric disorders (Mosheva, Korotkin, Gur, Weizman, & Gothelf, 2019) . The authors concluded that individuals with 22q11.2DS and psychiatric disorders are treated in a manner that is similar to those without 22q11.2DS
but that comorbid disorders common in 22q11.2DS may complicate treatment to some extent (Mosheva et al., 2019) .
In fact, most of the events that were reported as adverse effects are, or may be, common manifestations of 22q11.2DS, even in the absence of antipsychotic medication. Therefore, if and to what extent, the use of antipsychotics was responsible for the observed symptoms could not be established. For example, parkinsonism may not be uncommon in adults with 22q11.2DS Butcher et al., 2017) . Notably, individuals with 22q11.2DS have an increased risk of developing early-onset Parkinson's disease, with an average age at onset around age 40 years (Boot et al., 2018; Butcher, Kiehl, Hazrati, et al., 2013) . It is therefore important to differentiate between antipsychotic medication-induced extrapyramidal adverse effects and Parkinson's disease in this population. Dopamine transporter (DAT) imaging may be helpful in this (Booij, van Amelsvoort, & Boot, 2010) .
Furthermore, seizures and epilepsy, are more prevalent in individuals with 22q11.2DS than in the general population , and anticonvulsant treatment may be necessary , especially in those patients on clozapine .
In addition to hypocalcemia, antipsychotic medication, in particular clozapine, is an important contributor to a lowered seizure threshold in adults with 22q11.2DS that should alert clinicians .
Weight gain and metabolic syndrome are well-known adverse events of antipsychotic medication (Allison & Casey, 2001; Newcomer, 2007) . No studies assessed whether patients with 22q11.2DS
have an increased risk compared to other populations. However, in a study in adults with 22q11.2DS, it was found that psychotropic medication use, including but not exclusively antipsychotics, increased the odds of developing obesity with~2.5 times (Voll et al., 2017) . Given the comorbidity in 22q11.2DS, such as congenital heart defects, the observed risk of developing obesity during antipsychotic treatment may also warrant extra attention.
Thrombocytopenia was reported in several patients on antipsychotic medication. However, thrombocytopenia is a common manifestations of 22q11.2DS (Bassett et al., 2011) , and patients with 22q11.2DS typically have reduced platelet counts that usually do not require specific precautions (Lawrence, McDonald-McGinn, Zackai, & Sullivan, 2003) . A low white blood cell count was also frequently seen, including 15% (3 out of 20) of the patients on clozapine in the study by Butcher et al. (2015) , above general population expectations (Schulte, 2006) .
Given the increased prevalence of physical health problems in 22q11.2DS additional safety measures are recommended to prevent and monitor side effects and the occurrence of serious adverse events, see Box 1 for more information.
It is important to note that 50% of the case studies reported on clozapine use in 22q11.2DS, and this is much higher than expected (Nielsen, Røge, Schjerning, Sørensen, & Taylor, 2012) given that clozapine is usually prescribed for treatment-resistant schizophrenia. This may indicate a publication bias in the included case reports; as of yet, there is no evidence for increased prevalence of treatment-resistant schizophrenia in 22q11.2DS. It has been suggested that regular antipsychotics may have limited effect in 22q11.2DS (Verhoeven & Egger, 2015) but to the best of our knowledge, there are no randomized controlled trials supporting this hypothesis. It is likely, however, that clozapine is prescribed more often to patients with 22q11.2DS
given that clozapine is less likely than other antipsychotic medications to cause motor side effects (Casey, 1989; Rummel-Kluge et al., 2010) .
Given the multisystem nature of the condition, and the increased prevalence of physical health problems in 22q11.2DS, extra attention is recommended to prevent and monitor the occurrence of (serious) adverse events, see Box 1 for more information. BOX 1 Recommendations for prescribing antipsychotic medication in 22q11.2DS
| CONCLUSION
• As patients with 22q11.2DS may be at increased risk for movement disorders, a motor assessment should be part of standard clinical practice.
• Be aware that patients with 22q11.2DS are at increased risk for developing early-onset Parkinson's disease, with mean age at onset for motor signs relatively young at approximately 40 years. Molecular imaging may be helpful to distinguish Parkinson's disease from antipsychotic medication-induced parkinsonism.
• As most antipsychotic medications lower seizure threshold (particularly with clozapine), and 22q11.2DS is associated with hypocalcemic seizures, frequent monitoring of calcium levels is warranted.
• To reduce seizure risk, consider the addition of low-dose anticonvulsant when clozapine is initiated.
• Consider to consult a neurologist in case of, nonhypocalcemic, seizures.
• Promote daily exercise and a healthy diet to prevent weight gain during antipsychotic treatment.
• In general, it is recommended to monitor calcium levels, thyroid function and platelets on a regular basis, and to follow general management recommendations for adults with 22q11.2DS .
